Relay Therapeutics Inc- 詳細介紹、公司背景、業務範圍、財務數據以及市場表現

關於 Relay Therapeutics Inc 公司

Relay Therapeutics Inc. is a clinical-stage precision medicine company. The Company’s initial focus is on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. Its Dynamo platform integrates an array of computational and experimental approaches designed to drug protein targets that have previously been intractable or inadequately addressed. The Company’s lead product candidates, such as RLY-2608. It is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including RLY-2608. RLY-2608 is an allosteric, pan-mutant and isoform-selective phosphoinostide 3 kinase alphas (PI3Kα), inhibitor in clinical development. It is the lead program in its efforts to discover and develop mutant selective inhibitors of PI3Kα.

Relay Therapeutics Inc簡介



公司代碼RLAY

公司名稱Relay Therapeutics Inc

上市日期Jul 16, 2020

CEOPatel (Sanjiv K)

員工數量261

證券類型Ordinary Share

年結日Jul 16

公司地址60 Hampshire Street

城市CAMBRIDGE

上市交易所NASDAQ OMX - NASDAQ BASIC

國家United States of America

郵編02139

電話16173708837

網址https://relaytx.com/

公司代碼RLAY

上市日期Jul 16, 2020

CEOPatel (Sanjiv K)

Relay Therapeutics Inc公司高管



名稱

名稱/職務

職務

持股

持股變動

Dr. Mark Murcko, Ph.D.

Independent Director

996.95K

--

Mr. Brian R. Adams, J.D.

Chief Legal Officer, Secretary

178.96K

-19913.00%

Mr. Peter (Pete) Rahmer

Chief Corporate Development Officer

120.71K

-13038.00%

Mr. Douglas S. (Doug) Ingram, Esq., J.D.

Independent Director

25.00K

--

Dr. Sanjiv K. Patel, M.D.

President, Chief Executive Officer, Director

--

Dr. Donald A. Bergstrom, M.D., Ph.D.

President - Research and Development

--

Mr. Thomas (Tom) Catinazzo

Chief Financial Officer

--

Mr. Alexis A. Borisy

Independent Chairman of the Board

--

Dr. Linda A. Hill, Ph.D.

Independent Director

--

Dr. Sekar (Sek) Kathiresan, M.D.

Independent Director

--

名稱

名稱/職務

職務

持股

持股變動

Dr. Mark Murcko, Ph.D.

Independent Director

996.95K

--

Mr. Brian R. Adams, J.D.

Chief Legal Officer, Secretary

178.96K

-19913.00%

Mr. Peter (Pete) Rahmer

Chief Corporate Development Officer

120.71K

-13038.00%

Mr. Douglas S. (Doug) Ingram, Esq., J.D.

Independent Director

25.00K

--

Dr. Sanjiv K. Patel, M.D.

President, Chief Executive Officer, Director

--

Dr. Donald A. Bergstrom, M.D., Ph.D.

President - Research and Development

--

收入明細

FY2025Q3

FY2025Q2

FY2025Q1

FY2024

FY2024Q3

FY2023

FY2022

FY2021

FY2020

由於公司未披露，未能獲取相關數據

地區USD

名稱

營收

佔比

United States

0.00

0.00%

業務

地區

由於公司未披露，未能獲取相關數據

股東統計

更新時間: 11月18日週二

持股股東

股東類型

持股股東

佔比

SB Investment Advisers (UK) Limited

16.10%

Commodore Capital LP

9.81%

Point72 Asset Management, L.P.

8.52%

Casdin Capital, LLC

6.54%

BlackRock Institutional Trust Company, N.A.

6.05%

其他

52.98%

持股股東

佔比

SB Investment Advisers (UK) Limited

16.10%

Commodore Capital LP

9.81%

Point72 Asset Management, L.P.

8.52%

Casdin Capital, LLC

6.54%

BlackRock Institutional Trust Company, N.A.

6.05%

其他

52.98%

股東類型

持股股東

佔比

Hedge Fund

36.60%

Investment Advisor

27.59%

Private Equity

16.70%

Investment Advisor/Hedge Fund

12.95%

Research Firm

2.08%

Individual Investor

1.27%

Venture Capital

0.91%

Sovereign Wealth Fund

0.48%

Family Office

0.38%

其他

1.05%

機構持股



更新時間: 1月1日週四

報告期間

機構數

持股數

持股佔比

持股變動

2025Q4

458

170.00M

98.08%

-43.10M

2025Q3

457

168.31M

97.11%

-38.09M

2025Q2

460

180.78M

105.44%

-7.40M

2025Q1

473

175.15M

102.43%

-21.99M

2024Q4

463

170.97M

101.10%

-14.45M

2024Q3

455

166.81M

103.61%

+17.06M

2024Q2

434

132.20M

98.83%

-25.01M

2024Q1

423

138.51M

105.71%

-7.14M

2023Q4

410

132.38M

103.96%

-10.79M

2023Q3

396

136.20M

110.68%

-5.83M

股東持股明細



名稱

持股數

佔比

持股變動

變動比例

公告日期

SB Investment Advisers (UK) Limited

27.90M

16.1%

--

Sep 30, 2025

Commodore Capital LP

17.00M

9.81%

+3.65M

+27.34%

Sep 30, 2025

Point72 Asset Management, L.P.

14.77M

8.52%

+1.33M

+9.88%

Sep 30, 2025

Casdin Capital, LLC

11.34M

6.54%

-57.19K

-0.50%

Sep 30, 2025

BlackRock Institutional Trust Company, N.A.

10.48M

6.05%

-143.98K

-1.35%

Sep 30, 2025

The Vanguard Group, Inc.

9.37M

5.4%

+15.89K

+0.17%

Sep 30, 2025

Bellevue Asset Management AG

8.35M

4.82%

+114.74K

+1.39%

Sep 30, 2025

Tang Capital Management, LLC

8.07M

4.65%

--

Sep 30, 2025

State Street Investment Management (US)

5.07M

2.92%

-136.80K

-2.63%

Sep 30, 2025

Nextech Invest, Ltd.

3.85M

2.22%

--

Sep 30, 2025

持股ETF



更新時間: 12月6日週六

機構名稱

佔比

Virtus LifeSci Biotech Clinical Trials ETF

1.4%

Tema Oncology ETF

0.98%

ALPS Medical Breakthroughs ETF

0.51%

State Street SPDR S&P Biotech ETF

0.33%

ProShares Ultra Nasdaq Biotechnology

0.17%

Direxion Daily S&P Biotech Bull 3X Shares

0.16%

Avantis US Small Cap Equity ETF

0.14%

Invesco Nasdaq Biotechnology ETF

0.12%

Invesco RAFI US 1500 Small-Mid ETF

0.09%

iShares Biotechnology ETF

0.08%

Virtus LifeSci Biotech Clinical Trials ETF

佔比1.4%

Tema Oncology ETF

佔比0.98%

ALPS Medical Breakthroughs ETF

佔比0.51%

State Street SPDR S&P Biotech ETF

佔比0.33%

ProShares Ultra Nasdaq Biotechnology

佔比0.17%

Direxion Daily S&P Biotech Bull 3X Shares

佔比0.16%

Avantis US Small Cap Equity ETF

佔比0.14%

Invesco Nasdaq Biotechnology ETF

佔比0.12%

Invesco RAFI US 1500 Small-Mid ETF

佔比0.09%

iShares Biotechnology ETF

佔比0.08%

分紅派息



近5年累計派現 0.00 美元

公告日期

分紅計劃

股權登記日

現金發放日

除權除息日

暫無數據

拆合股



公告日期

除權除息日

類型

比率

暫無數據

公告日期

除權除息日

類型

比率

暫無數據